Emerging pharmacotherapy of tinnitus
Tinnitus, the perception of sound in the absence of an auditory stimulus, is perceived by about 1 in 10 adults, and for at least 1 in 100, tinnitus severely affects their quality of life. Because tinnitus is frequently associated with irritability, agitation, stress, insomnia, anxiety and depression...
Guardado en:
| Publicado: |
2009
|
|---|---|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_14728214_v14_n4_p687_Langguth http://hdl.handle.net/20.500.12110/paper_14728214_v14_n4_p687_Langguth |
| Aporte de: |
| id |
paper:paper_14728214_v14_n4_p687_Langguth |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_14728214_v14_n4_p687_Langguth2023-06-08T16:17:32Z Emerging pharmacotherapy of tinnitus Anticonvulsants Antidepressants Anxiolytics Auditory system GABA Glutamate Hearing Inner ear NMDA Pain Phantom perception acamprosate acetylsalicylic acid amitriptyline anticonvulsive agent antidepressant agent benzodiazepine derivative betahistine carbamazepine caroverine cinnarizine clonazepam dihydroergocristine dihydroergocryptine dopamine receptor blocking agent dopamine receptor stimulating agent flunarizine Ginkgo biloba extract lidocaine melatonin neramexane nicergoline nimodipine pentoxifylline piracetam piribedil placebo prednisolone sulpiride tocainide unindexed drug alcoholism anxiety auditory stimulation clinical feature clinical trial cognitive therapy depression drug blood level drug mechanism drug research heart arrhythmia human insomnia low drug dose nonhuman off label drug use quality of life review subarachnoid hemorrhage tinnitus Antineoplastic Combined Chemotherapy Protocols Anxiety Body Mass Index Cognition Disorders Cognitive Therapy Depression Depressive Disorder Health Status Humans Irritable Mood Lung Neoplasms Quality of Life Questionnaires Randomized Controlled Trials as Topic Receptors, Cannabinoid Risk Factors Sleep Initiation and Maintenance Disorders Stress Disorders, Post-Traumatic Time Factors Tinnitus United States United States Food and Drug Administration Tinnitus, the perception of sound in the absence of an auditory stimulus, is perceived by about 1 in 10 adults, and for at least 1 in 100, tinnitus severely affects their quality of life. Because tinnitus is frequently associated with irritability, agitation, stress, insomnia, anxiety and depression, the social and economic burdens of tinnitus can be enormous. No curative treatments are available. However, tinnitus symptoms can be alleviated to some extent. The most widespread management therapies consist of auditory stimulation and cognitive behavioral treatment, aiming at improving habituation and coping strategies. Available clinical trials vary in methodological rigor and have been performed for a considerable number of different drugs. None of the investigated drugs have demonstrated providing replicable long-term reduction of tinnitus impact in the majority of patients in excess of placebo effects. Accordingly, there are no FDA or European Medicines Agency approved drugs for the treatment of tinnitus. However, in spite of the lack of evidence, a large variety of different compounds are prescribed off-label. Therefore, more effective pharmacotherapies for this huge and still growing market are desperately needed and even a drug that produces only a small but significant effect would have an enormous therapeutic impact. This review describes current and emerging pharmacotherapies with current difficulties and limitations. In addition, it provides an estimate of the tinnitus market. Finally, it describes recent advances in the tinnitus field which may help overcome obstacles faced in the pharmacological treatment of tinnitus. These include incomplete knowledge of tinnitus pathophysiology, lack of well-established animal models, heterogeneity of different forms of tinnitus, difficulties in tinnitus assessment and outcome measurement and variability in clinical trial methodology. © 2009 Informa UK Ltd. 2009 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_14728214_v14_n4_p687_Langguth http://hdl.handle.net/20.500.12110/paper_14728214_v14_n4_p687_Langguth |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Anticonvulsants Antidepressants Anxiolytics Auditory system GABA Glutamate Hearing Inner ear NMDA Pain Phantom perception acamprosate acetylsalicylic acid amitriptyline anticonvulsive agent antidepressant agent benzodiazepine derivative betahistine carbamazepine caroverine cinnarizine clonazepam dihydroergocristine dihydroergocryptine dopamine receptor blocking agent dopamine receptor stimulating agent flunarizine Ginkgo biloba extract lidocaine melatonin neramexane nicergoline nimodipine pentoxifylline piracetam piribedil placebo prednisolone sulpiride tocainide unindexed drug alcoholism anxiety auditory stimulation clinical feature clinical trial cognitive therapy depression drug blood level drug mechanism drug research heart arrhythmia human insomnia low drug dose nonhuman off label drug use quality of life review subarachnoid hemorrhage tinnitus Antineoplastic Combined Chemotherapy Protocols Anxiety Body Mass Index Cognition Disorders Cognitive Therapy Depression Depressive Disorder Health Status Humans Irritable Mood Lung Neoplasms Quality of Life Questionnaires Randomized Controlled Trials as Topic Receptors, Cannabinoid Risk Factors Sleep Initiation and Maintenance Disorders Stress Disorders, Post-Traumatic Time Factors Tinnitus United States United States Food and Drug Administration |
| spellingShingle |
Anticonvulsants Antidepressants Anxiolytics Auditory system GABA Glutamate Hearing Inner ear NMDA Pain Phantom perception acamprosate acetylsalicylic acid amitriptyline anticonvulsive agent antidepressant agent benzodiazepine derivative betahistine carbamazepine caroverine cinnarizine clonazepam dihydroergocristine dihydroergocryptine dopamine receptor blocking agent dopamine receptor stimulating agent flunarizine Ginkgo biloba extract lidocaine melatonin neramexane nicergoline nimodipine pentoxifylline piracetam piribedil placebo prednisolone sulpiride tocainide unindexed drug alcoholism anxiety auditory stimulation clinical feature clinical trial cognitive therapy depression drug blood level drug mechanism drug research heart arrhythmia human insomnia low drug dose nonhuman off label drug use quality of life review subarachnoid hemorrhage tinnitus Antineoplastic Combined Chemotherapy Protocols Anxiety Body Mass Index Cognition Disorders Cognitive Therapy Depression Depressive Disorder Health Status Humans Irritable Mood Lung Neoplasms Quality of Life Questionnaires Randomized Controlled Trials as Topic Receptors, Cannabinoid Risk Factors Sleep Initiation and Maintenance Disorders Stress Disorders, Post-Traumatic Time Factors Tinnitus United States United States Food and Drug Administration Emerging pharmacotherapy of tinnitus |
| topic_facet |
Anticonvulsants Antidepressants Anxiolytics Auditory system GABA Glutamate Hearing Inner ear NMDA Pain Phantom perception acamprosate acetylsalicylic acid amitriptyline anticonvulsive agent antidepressant agent benzodiazepine derivative betahistine carbamazepine caroverine cinnarizine clonazepam dihydroergocristine dihydroergocryptine dopamine receptor blocking agent dopamine receptor stimulating agent flunarizine Ginkgo biloba extract lidocaine melatonin neramexane nicergoline nimodipine pentoxifylline piracetam piribedil placebo prednisolone sulpiride tocainide unindexed drug alcoholism anxiety auditory stimulation clinical feature clinical trial cognitive therapy depression drug blood level drug mechanism drug research heart arrhythmia human insomnia low drug dose nonhuman off label drug use quality of life review subarachnoid hemorrhage tinnitus Antineoplastic Combined Chemotherapy Protocols Anxiety Body Mass Index Cognition Disorders Cognitive Therapy Depression Depressive Disorder Health Status Humans Irritable Mood Lung Neoplasms Quality of Life Questionnaires Randomized Controlled Trials as Topic Receptors, Cannabinoid Risk Factors Sleep Initiation and Maintenance Disorders Stress Disorders, Post-Traumatic Time Factors Tinnitus United States United States Food and Drug Administration |
| description |
Tinnitus, the perception of sound in the absence of an auditory stimulus, is perceived by about 1 in 10 adults, and for at least 1 in 100, tinnitus severely affects their quality of life. Because tinnitus is frequently associated with irritability, agitation, stress, insomnia, anxiety and depression, the social and economic burdens of tinnitus can be enormous. No curative treatments are available. However, tinnitus symptoms can be alleviated to some extent. The most widespread management therapies consist of auditory stimulation and cognitive behavioral treatment, aiming at improving habituation and coping strategies. Available clinical trials vary in methodological rigor and have been performed for a considerable number of different drugs. None of the investigated drugs have demonstrated providing replicable long-term reduction of tinnitus impact in the majority of patients in excess of placebo effects. Accordingly, there are no FDA or European Medicines Agency approved drugs for the treatment of tinnitus. However, in spite of the lack of evidence, a large variety of different compounds are prescribed off-label. Therefore, more effective pharmacotherapies for this huge and still growing market are desperately needed and even a drug that produces only a small but significant effect would have an enormous therapeutic impact. This review describes current and emerging pharmacotherapies with current difficulties and limitations. In addition, it provides an estimate of the tinnitus market. Finally, it describes recent advances in the tinnitus field which may help overcome obstacles faced in the pharmacological treatment of tinnitus. These include incomplete knowledge of tinnitus pathophysiology, lack of well-established animal models, heterogeneity of different forms of tinnitus, difficulties in tinnitus assessment and outcome measurement and variability in clinical trial methodology. © 2009 Informa UK Ltd. |
| title |
Emerging pharmacotherapy of tinnitus |
| title_short |
Emerging pharmacotherapy of tinnitus |
| title_full |
Emerging pharmacotherapy of tinnitus |
| title_fullStr |
Emerging pharmacotherapy of tinnitus |
| title_full_unstemmed |
Emerging pharmacotherapy of tinnitus |
| title_sort |
emerging pharmacotherapy of tinnitus |
| publishDate |
2009 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_14728214_v14_n4_p687_Langguth http://hdl.handle.net/20.500.12110/paper_14728214_v14_n4_p687_Langguth |
| _version_ |
1768544611535421440 |